Publicaciones en las que colabora con Juan Macías (46)

2023

  1. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596

2022

  1. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

    Journal of Infection, Vol. 85, Núm. 3, pp. 322-326

2021

  1. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy

    Journal of Viral Hepatitis, Vol. 28, Núm. 6, pp. 878-886

  2. Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain

    HIV Medicine, Vol. 22, Núm. 5, pp. 379-386

  3. Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response

    AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127

  4. Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 9, pp. 2375-2379

  5. Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

    Clinical Microbiology and Infection

2020

  1. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32

  2. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 11, pp. 2810-2817

  3. Using machine learning methods to determine a typology of patients with HIVHCV infection to be treated with antivirals

    PLoS ONE, Vol. 15, Núm. 1

  4. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: A modeling analysis

    BMC Infectious Diseases, Vol. 20, Núm. 1

2019

  1. A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)

    Liver International, Vol. 39, Núm. 10, pp. 1918-1926

  2. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54

  3. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  4. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks

    Journal of Infection, Vol. 79, Núm. 1, pp. 30-35

  5. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278

  6. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

    HIV Medicine, Vol. 20, Núm. 6, pp. 359-367

  7. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

  8. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51

  9. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 16-24